While this update is being sent to all Wefunders, I want to direct it specifically to the 500+ investors who have voted with their finances to support our technology. 

We are proud that we have investors from Europe, North America, South America, Africa, Australia and Asia.  Our investors come from every region of the U.S. and from Canada. This gives us a heightened sense of encouragement and renews our dedication to our technology.
 
In the past, we reported the significance of our technology through updates.  We will be opening an “investors only” Facebook page to keep all investors informed and provide a platform for dialogue.  

 As we have explained, our initial focus, working in concert with Serum Institute, is to complete the recombinant production of our previously tested anti-HIV monoclonal antibody and then to conduct animal and clinical trials.  Serum Institute recognizes, as we have advocated, once our antibody is demonstrated to be effective in treating those with HIV, the next immediate step is then develop an anti-HIV vaccine that can be administered to prevent anyone from being infected with HIV.  Keep in mind that Serum Institute is the world largest provider of vaccines.  Thus, one can appreciate the logic of first producing the therapy for those with the virus and once confirming its effectiveness, then using that knowledge to prepare a vaccine that causes the body to produce its own anti-HIV antibodies.
 
Many attempts have been made by major companies to achieve what we expect to achieve – none have succeeded. As I have shared before, we welcome all attempts to provide a therapy or a vaccine against HIV.  As I have also pointed out, virtually every medical condition today is treated by a combination of therapies, whether it be cancer, antiretrovirals treating those with HIV today, and many many other medical conditions. Thus, treatment based on multiple therapies may be required to fully address the HIV pandemic.  However, we are confident that a full therapy will include our monoclonal antibody and indeed it may well be the single bullet necessary to a successful treatment. Time will tell.
 
We are well positioned with your vote of confidence and investment to move forward to develop our technology which has applicability both as a cure and will play a key role in producing an effective vaccine against HIV.
 
Also, as we have noted, the proprietary methodology we have used to develop our monoclonal antibody that targets and neutralizes the HIV virus is technology that can be used to create monoclonal antibodies against many many other diseases - both diseases affecting humans and animals. We intend to develop this technology as well. Your vote of confidence and your investment leads the way and opens the door to these possibilities. And we extend our appreciation.